(MENAFN- Navistrat Analytics) October 31, 2025- The increasing global burden of cancer remains a major revenue growth driver for the Antibody-Drug Conjugates (ADC) market. According to the American Cancer Society (2025), Non-Hodgkin lymphoma (NHL) continues to be one of the most prevalent malignancies in the United States, accounting for approximately 4% of all cancer diagnoses. In 2025, an estimated 80,350 new cases (45,140 men and 35,210 women) are expected, spanning both adult and pediatric populations. NHL-related mortality is projected to reach 19,390 deaths, including 11,060 men and 8,330 women. Lifetime risk is approximately 1 in 44 for men and 1 in 54 for women.

Supporting this trend in market expansion, in February 2025, Pfizer Inc. received FDA approval for a supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin). The new approval allows its use in combination with lenalidomide and a rituximab product for treating adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL).

While ADCs are emerging as a transformative approach in oncology therapy, their broader clinical adoption is still challenged by safety concerns. The toxicity profile of ADCs is complex and includes both frequent and unpredictable adverse effects such as neutropenia, ocular toxicity, thrombocytopenia, anemia, gastrointestinal injury, and musculoskeletal disorders, which can significantly limit their therapeutic utility in certain patient populations.

Segments market overview and growth Insights
Based on application, Antibody-Drug Conjugates (ADCs) market is segmented into oncology, autoimmune diseases, infectious diseases, and rare genetic disorders. Oncology segment contributed the largest share in 2024. The rising prevalence of other common cancers such as breast and cervical cancers further reinforces ADC market growth. As reported by the National Breast Cancer Foundation, one in eight women in the U.S. will develop breast cancer during her lifetime. In 2025 alone, it is estimated that 316,950 women and 2,800 men will be diagnosed with invasive breast cancer, alongside 59,080 new non-invasive (in situ) cases.

Regional market overview and growth insights
North America held the largest market share in 2024.This market expansion is primarily fueled by the increasing incidence of cancer worldwide alongside continuous improvements in ADC technologies. As reported by the American Cancer Society, approximately 13,360 new cases of invasive cervical cancer are expected to be diagnosed in the United States in 2025, with an estimated 4,320 related deaths. Notably, cervical precancerous lesions occur at a far higher rate than invasive disease, highlighting the ongoing need for more effective and targeted treatment options.

Competitive Landscape and Key Competitors
The Antibody-Drug Conjugates (ADCs) market is characterized by a fragmented structure, with many competitors holding a significant share of the market. List of major players included in the Antibody-Drug Conjugates (ADCs) market report are:

o AbbVie Inc.
o Pfizer Inc.
o Duality Biologics
o SystImmune, Inc.
o Adcendo
o Alentis Therapeutics
o Araris Biotech
o AdcentrX Therapeutics
o Daiichi Sankyo
o Astellas Pharma
o Oxford Biotherapeutics Limited
o GSK plc
o MediLink Therapeutics
o Takeda Pharmaceuticals
o ADC Therapeutics SA

Major strategic developments by leading competitors
Mycenax Biotech Inc.: In September 2025, Taiwan-based Mycenax Biotech Inc. entered a strategic partnership with Japan’s SPERA PHARMA Inc., combining expertise to deliver an integrated ADC and bioconjugates development platform — spanning linker/payload synthesis, drug-substance manufacturing, formulation, and aseptic fill-finish capabilities.

Boehringer Ingelheim: In January 2025, Boehringer Ingelheim licensed Synaffix B.V.’s clinical-stage ADC technology to expand its oncology pipeline, strengthening its position in next-generation ADC development.

Navistrat Analytics has segmented the Antibody-Drug Conjugates (ADCs) market based on product type, mechanism of action, target, application, end-use, and region:
• Product Type Outlook (Revenue, USD Billion; 2022-2032)
o Antibody Components
o Cytotoxic Payloads
o Linkers
o Complete ADCs

• Mechanism of Action Outlook (Revenue, USD Billion; 2022-2032)
o Microtubule Inhibitors
o DNA Damaging Agents

• Target Outlook (Revenue, USD Billion; 2022-2032)
o HER2
o CD22
o CD30
o Others

• Application Outlook (Revenue, USD Billion; 2022-2032)
o Oncology
o Autoimmune Diseases
o Infectious Diseases
o Rare Genetic Disorders

• End-Use Outlook (Revenue, USD Billion; 2022-2032)
o Hospitals & Cancer Clinics
o Research Institutes & Academic Centers
o Pharmaceutical & Biotechnology Companies
o Contract Development & Manufacturing Organizations (CDMOs)

• Regional Outlook (Revenue, USD Billion; 2022-2032)
o North America
a. U.S.
b. Canada
c. Mexico
o Europe
a. Germany
b. France
c. U.K.
d. Italy
e. Spain
f. Benelux
g. Nordic Countries
h. Rest of Europe
o Asia Pacific
a. China
b. India
c. Japan
d. South Korea
e. Oceania
f. ASEAN Countries
g. Rest of APAC
o Latin America
a. Brazil
b. Rest of LATAM
o Middle East & Africa
a. GCC Countries
b. South Africa
c. Israel
d. Turkey
e. Rest of MEA

MENAFN31102025008152017457ID1110275195